N@N

Jessica Fye Maintained (VRTX) at Buy with Increased Target to $438 on, Feb 1st, 2024

Jessica Fye of JP Morgan, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $390 to $438 on, Feb 1st, 2024.

Jessica has made no other calls on VRTX in the last 4 months.

There are 12 other peers that have a rating on VRTX. Out of the 12 peers that are also analyzing VRTX, 4 agree with Jessica's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Naz Rahman of "Maxim Group" Downgraded from Strong Buy to Hold on, Wednesday, January 31st, 2024
• Brian Abrahams of "RBC Capital" Maintained at Hold with Increased Target to $379 on, Thursday, December 14th, 2023
• Paul Matteis of "Stifel" Reiterated at Hold and Held Target at $373 on, Wednesday, November 22nd, 2023
• Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $364 on, Wednesday, November 8th, 2023

These are the ratings of the 8 analyists that currently disagree with Jessica

---

• Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $508 on, Wednesday, January 31st, 2024
• Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $559 on, Wednesday, January 31st, 2024
• Whitney Ijem of "Canaccord Genuity" Downgraded from Hold to Strong Sell and Increased Target to $379 on, Wednesday, January 24th, 2024
• Olivia Brayer of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $440 on, Wednesday, January 24th, 2024
• Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $397 on, Monday, December 11th, 2023
• Gena Wang of "Barclays" Maintained at Buy with Increased Target to $415 on, Monday, December 11th, 2023
• Evan Seigerman of "BMO Capital" Maintained at Buy with Increased Target to $415 on, Tuesday, November 7th, 2023
• Eric Schmidt of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $370 on, Tuesday, October 17th, 2023

Contributing Sources

---